{ "source": "Nasdaq Nordic Company News", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "status": "retrieved", "company": "XVIVO Perfusion", "reports": [ { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T20:06:43Z", "company": "Xvivo Perfusion AB", "title": "Delårsrapport januari - juni 2026", "category": "Halvårsrapport", "date": "2026-07-14", "language": "sv", "report_type": "interim-report", "fiscal_year": 2026, "quarter": "q2", "period": "2026-q2", "report_key": "2026:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=b0b5abbcfdd4cd40798dae4c97bcff593&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2026-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2026-q2\\release.txt", "attachments": [ { "label": "XVIVO Delarsrapport Januari Juni 2026.pdf", "url": "https://attachment.news.eu.nasdaq.com/a0680c241d076247be055e08da27e968d", "final_url": "https://attachment.news.eu.nasdaq.com/a0680c241d076247be055e08da27e968d", "filename": "XVIVO_Delarsrapport_Januari_Juni_2026.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2026-q2\\XVIVO_Delarsrapport_Januari_Juni_2026.pdf", "content_type": "application/pdf", "size": 1694982, "sha256": "8bffac95165c5c8b26a6ba714b0d207045823072c1bdc2848938ba7a2f567499", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2026-q2\\XVIVO_Delarsrapport_Januari_Juni_2026.pdf", "filename": "XVIVO_Delarsrapport_Januari_Juni_2026.pdf", "extension": ".pdf", "size": 1694982, "sha256": "8bffac95165c5c8b26a6ba714b0d207045823072c1bdc2848938ba7a2f567499", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2026-q2\\extracted\\XVIVO_Delarsrapport_Januari_Juni_2026\\XVIVO_Delarsrapport_Januari_Juni_2026.txt", "text_chars": 79405, "metadata": { "page_count": 26, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2026-q2\\extracted\\XVIVO_Delarsrapport_Januari_Juni_2026\\XVIVO_Delarsrapport_Januari_Juni_2026.extraction.json" } } ], "announcement_id": "1453920", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T20:06:48Z", "company": "Xvivo Perfusion AB", "title": "Delårsrapport januari - mars 2026", "category": "Interimsrapport", "date": "2026-04-24", "language": "sv", "report_type": "interim-report", "fiscal_year": 2026, "quarter": "q1", "period": "2026-q1", "report_key": "2026:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=baa5bcbc3fc307ce23f0fdb57d979b599&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2026-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2026-q1\\release.txt", "attachments": [ { "label": "XVIVO Delarsrapport Q1 2026.pdf", "url": "https://attachment.news.eu.nasdaq.com/a941583dc581b0dbcdcc0aea16c08ba15", "final_url": "https://attachment.news.eu.nasdaq.com/a941583dc581b0dbcdcc0aea16c08ba15", "filename": "XVIVO_Delarsrapport_Q1_2026.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2026-q1\\XVIVO_Delarsrapport_Q1_2026.pdf", "content_type": "application/pdf", "size": 1607086, "sha256": "078f9acc5643a946b13bcf798e7c5bdb9f62511784342e23069ab0140b8888ce", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2026-q1\\XVIVO_Delarsrapport_Q1_2026.pdf", "filename": "XVIVO_Delarsrapport_Q1_2026.pdf", "extension": ".pdf", "size": 1607086, "sha256": "078f9acc5643a946b13bcf798e7c5bdb9f62511784342e23069ab0140b8888ce", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2026-q1\\extracted\\XVIVO_Delarsrapport_Q1_2026\\XVIVO_Delarsrapport_Q1_2026.txt", "text_chars": 68483, "metadata": { "page_count": 23, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2026-q1\\extracted\\XVIVO_Delarsrapport_Q1_2026\\XVIVO_Delarsrapport_Q1_2026.extraction.json" } } ], "announcement_id": "1436734", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T20:06:58Z", "company": "Xvivo Perfusion AB", "title": "Årsredovisning 2025", "category": "Bokslut och Verksamhetsberättelse", "date": "2026-04-01", "language": "sv", "report_type": "annual-report", "fiscal_year": 2025, "quarter": "annual", "period": "2025-annual", "report_key": "2025:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=b7bdf0373745ab8206612b6c745615d4e&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-annual\\release.txt", "attachments": [ { "label": "XVIVO Perfusion Ab publ Arsredovisning 2025.pdf", "url": "https://attachment.news.eu.nasdaq.com/a615f74af236f4a6f9efc8f84ec007fd2", "final_url": "https://attachment.news.eu.nasdaq.com/a615f74af236f4a6f9efc8f84ec007fd2", "filename": "XVIVO_Perfusion_Ab_publ_Arsredovisning_2025.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-annual\\XVIVO_Perfusion_Ab_publ_Arsredovisning_2025.pdf", "content_type": "application/pdf", "size": 6396669, "sha256": "32699933fab9b80e4730f5b5cbafc1a712cdd995bc233a139d2d379038636a3d", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-annual\\XVIVO_Perfusion_Ab_publ_Arsredovisning_2025.pdf", "filename": "XVIVO_Perfusion_Ab_publ_Arsredovisning_2025.pdf", "extension": ".pdf", "size": 6396669, "sha256": "32699933fab9b80e4730f5b5cbafc1a712cdd995bc233a139d2d379038636a3d", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-annual\\extracted\\XVIVO_Perfusion_Ab_publ_Arsredovisning_2025\\XVIVO_Perfusion_Ab_publ_Arsredovisning_2025.txt", "text_chars": 297663, "metadata": { "page_count": 114, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-annual\\extracted\\XVIVO_Perfusion_Ab_publ_Arsredovisning_2025\\XVIVO_Perfusion_Ab_publ_Arsredovisning_2025.extraction.json" } } ], "announcement_id": "1430812", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T20:07:00Z", "company": "Xvivo Perfusion AB", "title": "Bokslutskommuniké 2025", "category": "Bokslutskommuniké", "date": "2026-01-27", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2025, "quarter": "q4", "period": "2025-q4", "report_key": "2025:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=bbf1e323680987107e9ade3e78893dd7b&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-q4\\release.txt", "attachments": [ { "label": "XVIVO Bokslutskommunike 2025.pdf", "url": "https://attachment.news.eu.nasdaq.com/aab3317c3c213f82c4959f115aec7047b", "final_url": "https://attachment.news.eu.nasdaq.com/aab3317c3c213f82c4959f115aec7047b", "filename": "XVIVO_Bokslutskommunike_2025.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-q4\\XVIVO_Bokslutskommunike_2025.pdf", "content_type": "application/pdf", "size": 2150800, "sha256": "be70920de31e7ac3a3e270360657c3be51e0ce8aff4d9076895aaafd02388adf", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-q4\\XVIVO_Bokslutskommunike_2025.pdf", "filename": "XVIVO_Bokslutskommunike_2025.pdf", "extension": ".pdf", "size": 2150800, "sha256": "be70920de31e7ac3a3e270360657c3be51e0ce8aff4d9076895aaafd02388adf", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-q4\\extracted\\XVIVO_Bokslutskommunike_2025\\XVIVO_Bokslutskommunike_2025.txt", "text_chars": 84932, "metadata": { "page_count": 27, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-q4\\extracted\\XVIVO_Bokslutskommunike_2025\\XVIVO_Bokslutskommunike_2025.extraction.json" } } ], "announcement_id": "1415605", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T20:07:06Z", "company": "Xvivo Perfusion AB", "title": "Delårsrapport januari - september 2025", "category": "Interimsrapport", "date": "2025-10-23", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q3", "period": "2025-q3", "report_key": "2025:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=bb846263b20d9eb4e5735e73b7f34e05c&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-q3\\release.txt", "attachments": [ { "label": "XVIVO Delarsrapport Q3 2025.pdf", "url": "https://attachment.news.eu.nasdaq.com/a6083fd0d00915dbdf5eb7c7061d09e71", "final_url": "https://attachment.news.eu.nasdaq.com/a6083fd0d00915dbdf5eb7c7061d09e71", "filename": "XVIVO_Delarsrapport_Q3_2025.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-q3\\XVIVO_Delarsrapport_Q3_2025.pdf", "content_type": "application/pdf", "size": 2156609, "sha256": "4c2f06df608966130ce293f0bf24c6ded2a92cdad0c28e048797bd1fc616aaf2", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-q3\\XVIVO_Delarsrapport_Q3_2025.pdf", "filename": "XVIVO_Delarsrapport_Q3_2025.pdf", "extension": ".pdf", "size": 2156609, "sha256": "4c2f06df608966130ce293f0bf24c6ded2a92cdad0c28e048797bd1fc616aaf2", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-q3\\extracted\\XVIVO_Delarsrapport_Q3_2025\\XVIVO_Delarsrapport_Q3_2025.txt", "text_chars": 88291, "metadata": { "page_count": 28, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-q3\\extracted\\XVIVO_Delarsrapport_Q3_2025\\XVIVO_Delarsrapport_Q3_2025.extraction.json" } } ], "announcement_id": "1396023", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T20:07:11Z", "company": "Xvivo Perfusion AB", "title": "Delårsrapport januari-juni 2025", "category": "Halvårsrapport", "date": "2025-07-11", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q2", "period": "2025-q2", "report_key": "2025:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=b5e08de572f10d1b46f1f1504c3ed95ca&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-q2\\release.txt", "attachments": [ { "label": "XVIVO Delarsrapport Q2 2025.pdf", "url": "https://attachment.news.eu.nasdaq.com/ac2517d0001a6275598b4a18f26df418f", "final_url": "https://attachment.news.eu.nasdaq.com/ac2517d0001a6275598b4a18f26df418f", "filename": "XVIVO_Delarsrapport_Q2_2025.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-q2\\XVIVO_Delarsrapport_Q2_2025.pdf", "content_type": "application/pdf", "size": 2076382, "sha256": "9ca6c576f22c5d350885f34533cf2db39c3cd319d9ff9ef814cedf466f94ba27", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-q2\\XVIVO_Delarsrapport_Q2_2025.pdf", "filename": "XVIVO_Delarsrapport_Q2_2025.pdf", "extension": ".pdf", "size": 2076382, "sha256": "9ca6c576f22c5d350885f34533cf2db39c3cd319d9ff9ef814cedf466f94ba27", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-q2\\extracted\\XVIVO_Delarsrapport_Q2_2025\\XVIVO_Delarsrapport_Q2_2025.txt", "text_chars": 83790, "metadata": { "page_count": 28, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-q2\\extracted\\XVIVO_Delarsrapport_Q2_2025\\XVIVO_Delarsrapport_Q2_2025.extraction.json" } } ], "announcement_id": "1377423", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T20:07:16Z", "company": "Xvivo Perfusion AB", "title": "Delårsrapport januari-mars 2025", "category": "Interimsrapport", "date": "2025-04-24", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q1", "period": "2025-q1", "report_key": "2025:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=bf195a344a886c58b9323b9e085ea0189&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-q1\\release.txt", "attachments": [ { "label": "XVIVO Delarsrapport Q1 2025.pdf", "url": "https://attachment.news.eu.nasdaq.com/a0630e41971a7e7f83d3e62a07a7dd3b4", "final_url": "https://attachment.news.eu.nasdaq.com/a0630e41971a7e7f83d3e62a07a7dd3b4", "filename": "XVIVO_Delarsrapport_Q1_2025.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-q1\\XVIVO_Delarsrapport_Q1_2025.pdf", "content_type": "application/pdf", "size": 2041323, "sha256": "58b696e541849758b47240a3be059d9cee3d470c19393430a39a15701c5de5a0", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-q1\\XVIVO_Delarsrapport_Q1_2025.pdf", "filename": "XVIVO_Delarsrapport_Q1_2025.pdf", "extension": ".pdf", "size": 2041323, "sha256": "58b696e541849758b47240a3be059d9cee3d470c19393430a39a15701c5de5a0", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-q1\\extracted\\XVIVO_Delarsrapport_Q1_2025\\XVIVO_Delarsrapport_Q1_2025.txt", "text_chars": 70692, "metadata": { "page_count": 23, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2025-q1\\extracted\\XVIVO_Delarsrapport_Q1_2025\\XVIVO_Delarsrapport_Q1_2025.extraction.json" } } ], "announcement_id": "1357598", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T20:07:25Z", "company": "Xvivo Perfusion AB", "title": "Årsredovisning 2024", "category": "Bokslut och Verksamhetsberättelse", "date": "2025-04-02", "language": "sv", "report_type": "annual-report", "fiscal_year": 2024, "quarter": "annual", "period": "2024-annual", "report_key": "2024:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=b038f773b17cd4567da77aeb392d6fe21&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-annual\\release.txt", "attachments": [ { "label": "XVIVO Perfusion AB publ Arsredovisning 2024.pdf", "url": "https://attachment.news.eu.nasdaq.com/a479f81637801444ef3fec443441821b6", "final_url": "https://attachment.news.eu.nasdaq.com/a479f81637801444ef3fec443441821b6", "filename": "XVIVO_Perfusion_AB_publ_Arsredovisning_2024.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-annual\\XVIVO_Perfusion_AB_publ_Arsredovisning_2024.pdf", "content_type": "application/pdf", "size": 4991829, "sha256": "e009304fe3af6debb56cf1237544516db5b42015773d9272b02295c98cd55975", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-annual\\XVIVO_Perfusion_AB_publ_Arsredovisning_2024.pdf", "filename": "XVIVO_Perfusion_AB_publ_Arsredovisning_2024.pdf", "extension": ".pdf", "size": 4991829, "sha256": "e009304fe3af6debb56cf1237544516db5b42015773d9272b02295c98cd55975", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-annual\\extracted\\XVIVO_Perfusion_AB_publ_Arsredovisning_2024\\XVIVO_Perfusion_AB_publ_Arsredovisning_2024.txt", "text_chars": 309968, "metadata": { "page_count": 119, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-annual\\extracted\\XVIVO_Perfusion_AB_publ_Arsredovisning_2024\\XVIVO_Perfusion_AB_publ_Arsredovisning_2024.extraction.json" } } ], "announcement_id": "1353310", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T20:07:28Z", "company": "Xvivo Perfusion AB", "title": "Bokslutskommuniké 2024", "category": "Bokslutskommuniké", "date": "2025-01-28", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2024, "quarter": "q4", "period": "2024-q4", "report_key": "2024:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=b4a0c118a9f163b9f0d600cee15ee0e45&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-q4\\release.txt", "attachments": [ { "label": "XVIVO Bokslutskommunike 2024.pdf", "url": "https://attachment.news.eu.nasdaq.com/a3fca5cd2988e9f95e40dcea4b9ae30c1", "final_url": "https://attachment.news.eu.nasdaq.com/a3fca5cd2988e9f95e40dcea4b9ae30c1", "filename": "XVIVO_Bokslutskommunike_2024.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-q4\\XVIVO_Bokslutskommunike_2024.pdf", "content_type": "application/pdf", "size": 1244085, "sha256": "18d8631ba7e30d2b81ea8cbe5d327551e3a610d98a87d0f1098e0553a520d40c", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-q4\\XVIVO_Bokslutskommunike_2024.pdf", "filename": "XVIVO_Bokslutskommunike_2024.pdf", "extension": ".pdf", "size": 1244085, "sha256": "18d8631ba7e30d2b81ea8cbe5d327551e3a610d98a87d0f1098e0553a520d40c", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-q4\\extracted\\XVIVO_Bokslutskommunike_2024\\XVIVO_Bokslutskommunike_2024.txt", "text_chars": 98297, "metadata": { "page_count": 30, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-q4\\extracted\\XVIVO_Bokslutskommunike_2024\\XVIVO_Bokslutskommunike_2024.extraction.json" } } ], "announcement_id": "1339206", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T20:07:33Z", "company": "Xvivo Perfusion AB", "title": "Delårsrapport januari-september 2024", "category": "Interimsrapport", "date": "2024-10-24", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q3", "period": "2024-q3", "report_key": "2024:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=b9d7a92cabb120715b62146a39a9c4dd9&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-q3\\release.txt", "attachments": [ { "label": "XVIVO Delarsrapport Januari September 2024.pdf", "url": "https://attachment.news.eu.nasdaq.com/aafd86ee6455d0f214bead4e7b87db27d", "final_url": "https://attachment.news.eu.nasdaq.com/aafd86ee6455d0f214bead4e7b87db27d", "filename": "XVIVO_Delarsrapport_Januari_September_2024.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-q3\\XVIVO_Delarsrapport_Januari_September_2024.pdf", "content_type": "application/pdf", "size": 1235790, "sha256": "6d244769370a20ed82430da4bf230cb52faf47597c0a042d254b43e919d65117", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-q3\\XVIVO_Delarsrapport_Januari_September_2024.pdf", "filename": "XVIVO_Delarsrapport_Januari_September_2024.pdf", "extension": ".pdf", "size": 1235790, "sha256": "6d244769370a20ed82430da4bf230cb52faf47597c0a042d254b43e919d65117", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-q3\\extracted\\XVIVO_Delarsrapport_Januari_September_2024\\XVIVO_Delarsrapport_Januari_September_2024.txt", "text_chars": 93302, "metadata": { "page_count": 30, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-q3\\extracted\\XVIVO_Delarsrapport_Januari_September_2024\\XVIVO_Delarsrapport_Januari_September_2024.extraction.json" } } ], "announcement_id": "1323095", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T20:07:38Z", "company": "Xvivo Perfusion AB", "title": "Delårsrapport januari - juni 2024", "category": "Halvårsrapport", "date": "2024-07-12", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q2", "period": "2024-q2", "report_key": "2024:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=be961082034cceda71a6bd987a87c6201&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-q2\\release.txt", "attachments": [ { "label": "XVIVO Delarsrapport Q2 2024.pdf", "url": "https://attachment.news.eu.nasdaq.com/ae4bc39452b8c18d57d41d1a3d79b4dd3", "final_url": "https://attachment.news.eu.nasdaq.com/ae4bc39452b8c18d57d41d1a3d79b4dd3", "filename": "XVIVO_Delarsrapport_Q2_2024.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-q2\\XVIVO_Delarsrapport_Q2_2024.pdf", "content_type": "application/pdf", "size": 1214681, "sha256": "c8646a6f2eeaf79da17e0c576eb1caaa49ef7226b8b46765c02aa7700fada482", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-q2\\XVIVO_Delarsrapport_Q2_2024.pdf", "filename": "XVIVO_Delarsrapport_Q2_2024.pdf", "extension": ".pdf", "size": 1214681, "sha256": "c8646a6f2eeaf79da17e0c576eb1caaa49ef7226b8b46765c02aa7700fada482", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-q2\\extracted\\XVIVO_Delarsrapport_Q2_2024\\XVIVO_Delarsrapport_Q2_2024.txt", "text_chars": 84644, "metadata": { "page_count": 28, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-q2\\extracted\\XVIVO_Delarsrapport_Q2_2024\\XVIVO_Delarsrapport_Q2_2024.extraction.json" } } ], "announcement_id": "1306132", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T20:07:44Z", "company": "Xvivo Perfusion AB", "title": "Delårsrapport januari-mars 2024", "category": "Interimsrapport", "date": "2024-04-24", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q1", "period": "2024-q1", "report_key": "2024:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b4f1d0d88309037de861a05447499097e&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-q1\\release.txt", "attachments": [ { "label": "XVIVO Delarsrapport Q1 2024.pdf", "url": "https://attachment.news.eu.nasdaq.com/afd08b19f207c3c067419219657cee68a", "final_url": "https://attachment.news.eu.nasdaq.com/afd08b19f207c3c067419219657cee68a", "filename": "XVIVO_Delarsrapport_Q1_2024.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-q1\\XVIVO_Delarsrapport_Q1_2024.pdf", "content_type": "application/pdf", "size": 1178715, "sha256": "07e7c535f884c16dcee0b372ced28af7741716c998b9b8288ffd6d6d277a0c87", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-q1\\XVIVO_Delarsrapport_Q1_2024.pdf", "filename": "XVIVO_Delarsrapport_Q1_2024.pdf", "extension": ".pdf", "size": 1178715, "sha256": "07e7c535f884c16dcee0b372ced28af7741716c998b9b8288ffd6d6d277a0c87", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-q1\\extracted\\XVIVO_Delarsrapport_Q1_2024\\XVIVO_Delarsrapport_Q1_2024.txt", "text_chars": 73866, "metadata": { "page_count": 24, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2024-q1\\extracted\\XVIVO_Delarsrapport_Q1_2024\\XVIVO_Delarsrapport_Q1_2024.extraction.json" } } ], "announcement_id": "1289948", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T20:07:55Z", "company": "Xvivo Perfusion AB", "title": "Årsredovisning 2023", "category": "Bokslut och Verksamhetsberättelse", "date": "2024-04-04", "language": "sv", "report_type": "annual-report", "fiscal_year": 2023, "quarter": "annual", "period": "2023-annual", "report_key": "2023:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=b27aec971d18b8113be546f58ba6a73c3&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-annual\\release.txt", "attachments": [ { "label": "XVIVO Perfusion AB publ Arsredovisning 2023.pdf", "url": "https://attachment.news.eu.nasdaq.com/adb17d80609340e8198aeadcdb3edac22", "final_url": "https://attachment.news.eu.nasdaq.com/adb17d80609340e8198aeadcdb3edac22", "filename": "XVIVO_Perfusion_AB_publ_Arsredovisning_2023.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-annual\\XVIVO_Perfusion_AB_publ_Arsredovisning_2023.pdf", "content_type": "application/pdf", "size": 6860201, "sha256": "a966b828525b8879f5bce518b9e132e61bbb641a3d838f80a85244b8ac8c5acb", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-annual\\XVIVO_Perfusion_AB_publ_Arsredovisning_2023.pdf", "filename": "XVIVO_Perfusion_AB_publ_Arsredovisning_2023.pdf", "extension": ".pdf", "size": 6860201, "sha256": "a966b828525b8879f5bce518b9e132e61bbb641a3d838f80a85244b8ac8c5acb", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-annual\\extracted\\XVIVO_Perfusion_AB_publ_Arsredovisning_2023\\XVIVO_Perfusion_AB_publ_Arsredovisning_2023.txt", "text_chars": 328330, "metadata": { "page_count": 127, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-annual\\extracted\\XVIVO_Perfusion_AB_publ_Arsredovisning_2023\\XVIVO_Perfusion_AB_publ_Arsredovisning_2023.extraction.json" } } ], "announcement_id": "1285880", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T20:07:59Z", "company": "Xvivo Perfusion AB", "title": "XVIVO avlämnar Bokslutskommuniké 2023", "category": "Bokslutskommuniké", "date": "2024-01-25", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2023, "quarter": "q4", "period": "2023-q4", "report_key": "2023:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=ba63cd9fd99559986b54b95d5b2a3b032&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-q4\\release.txt", "attachments": [ { "label": "XVIVO Bokslutskommunike 2023.pdf", "url": "https://attachment.news.eu.nasdaq.com/a9f7506bf556d77c16fc28778ffd31219", "final_url": "https://attachment.news.eu.nasdaq.com/a9f7506bf556d77c16fc28778ffd31219", "filename": "XVIVO_Bokslutskommunike_2023.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-q4\\XVIVO_Bokslutskommunike_2023.pdf", "content_type": "application/pdf", "size": 896073, "sha256": "0c2d8c4e7dfaee195a580c9dabbcf0996d49aa0f4fc6e7c5563dc388014a2c3a", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-q4\\XVIVO_Bokslutskommunike_2023.pdf", "filename": "XVIVO_Bokslutskommunike_2023.pdf", "extension": ".pdf", "size": 896073, "sha256": "0c2d8c4e7dfaee195a580c9dabbcf0996d49aa0f4fc6e7c5563dc388014a2c3a", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-q4\\extracted\\XVIVO_Bokslutskommunike_2023\\XVIVO_Bokslutskommunike_2023.txt", "text_chars": 102592, "metadata": { "page_count": 28, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-q4\\extracted\\XVIVO_Bokslutskommunike_2023\\XVIVO_Bokslutskommunike_2023.extraction.json" } } ], "announcement_id": "1270670", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T20:08:03Z", "company": "Xvivo Perfusion AB", "title": "Delårsrapport januari-September 2023", "category": "Interimsrapport", "date": "2023-10-24", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q3", "period": "2023-q3", "report_key": "2023:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=b4caeb20a26fd9f1b2dfaad1117675c68&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-q3\\release.txt", "attachments": [ { "label": "XVIVO Delarsrapport Januari September 2023.pdf", "url": "https://attachment.news.eu.nasdaq.com/a945137115ed567efad38b5e038ff0c75", "final_url": "https://attachment.news.eu.nasdaq.com/a945137115ed567efad38b5e038ff0c75", "filename": "XVIVO_Delarsrapport_Januari_September_2023.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-q3\\XVIVO_Delarsrapport_Januari_September_2023.pdf", "content_type": "application/pdf", "size": 882590, "sha256": "6f9acea7642de192e012480e7d1d576d625601d3911a15461a49342a64288a45", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-q3\\XVIVO_Delarsrapport_Januari_September_2023.pdf", "filename": "XVIVO_Delarsrapport_Januari_September_2023.pdf", "extension": ".pdf", "size": 882590, "sha256": "6f9acea7642de192e012480e7d1d576d625601d3911a15461a49342a64288a45", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-q3\\extracted\\XVIVO_Delarsrapport_Januari_September_2023\\XVIVO_Delarsrapport_Januari_September_2023.txt", "text_chars": 97520, "metadata": { "page_count": 28, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-q3\\extracted\\XVIVO_Delarsrapport_Januari_September_2023\\XVIVO_Delarsrapport_Januari_September_2023.extraction.json" } } ], "announcement_id": "1254214", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T20:08:08Z", "company": "Xvivo Perfusion AB", "title": "XVIVO avlämnar delårsrapport januari-juni 2023", "category": "Halvårsrapport", "date": "2023-07-13", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q2", "period": "2023-q2", "report_key": "2023:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=bcc1abc698b1d0ec4edb416453c715854&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-q2\\release.txt", "attachments": [ { "label": "XVIVO Delarsrapport Januari Juni 2023.pdf", "url": "https://attachment.news.eu.nasdaq.com/a07f7d275af50fb575d75dd0872902212", "final_url": "https://attachment.news.eu.nasdaq.com/a07f7d275af50fb575d75dd0872902212", "filename": "XVIVO_Delarsrapport_Januari_Juni_2023.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-q2\\XVIVO_Delarsrapport_Januari_Juni_2023.pdf", "content_type": "application/pdf", "size": 865865, "sha256": "a9fb480625eb2301c97255699c01b78794f8c9d63c2c0c9f534a23378ec8d359", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-q2\\XVIVO_Delarsrapport_Januari_Juni_2023.pdf", "filename": "XVIVO_Delarsrapport_Januari_Juni_2023.pdf", "extension": ".pdf", "size": 865865, "sha256": "a9fb480625eb2301c97255699c01b78794f8c9d63c2c0c9f534a23378ec8d359", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-q2\\extracted\\XVIVO_Delarsrapport_Januari_Juni_2023\\XVIVO_Delarsrapport_Januari_Juni_2023.txt", "text_chars": 88874, "metadata": { "page_count": 26, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-q2\\extracted\\XVIVO_Delarsrapport_Januari_Juni_2023\\XVIVO_Delarsrapport_Januari_Juni_2023.extraction.json" } } ], "announcement_id": "1238150", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T20:08:13Z", "company": "Xvivo Perfusion AB", "title": "XVIVO avlämnar delårsrapport januari-mars 2023", "category": "Interimsrapport", "date": "2023-04-24", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q1", "period": "2023-q1", "report_key": "2023:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=ba839d0df61e44949f3a88008d3e007b3&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-q1\\release.txt", "attachments": [ { "label": "XVIVO Delarsrapport Q1 2023.pdf", "url": "https://attachment.news.eu.nasdaq.com/a01a8f1549d0c7ef8ac32bacf15691322", "final_url": "https://attachment.news.eu.nasdaq.com/a01a8f1549d0c7ef8ac32bacf15691322", "filename": "XVIVO_Delarsrapport_Q1_2023.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-q1\\XVIVO_Delarsrapport_Q1_2023.pdf", "content_type": "application/pdf", "size": 818348, "sha256": "52cffa027d836b5446c9f546895c872a7b1d3b202caf8749688a45ae46a10345", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-q1\\XVIVO_Delarsrapport_Q1_2023.pdf", "filename": "XVIVO_Delarsrapport_Q1_2023.pdf", "extension": ".pdf", "size": 818348, "sha256": "52cffa027d836b5446c9f546895c872a7b1d3b202caf8749688a45ae46a10345", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-q1\\extracted\\XVIVO_Delarsrapport_Q1_2023\\XVIVO_Delarsrapport_Q1_2023.txt", "text_chars": 71155, "metadata": { "page_count": 22, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xvivo-perfusion\\nasdaq-reports\\reports\\2023-q1\\extracted\\XVIVO_Delarsrapport_Q1_2023\\XVIVO_Delarsrapport_Q1_2023.extraction.json" } } ], "announcement_id": "1221711", "status": "retrieved" } ], "attempts": [ { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=XVIVO+Perfusion&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 0, "pagination": "row-offset", "query_text": "XVIVO Perfusion", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "5387888e46725fe10c50d0888582dd02508d1b9eb0264fe7f8f33ae41c77e30b" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=XVIVO+Perfusion&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=100&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 100, "pagination": "row-offset", "query_text": "XVIVO Perfusion", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "b82fb2b940fb80b828fd8b55304696633b265d36390e4a6cc45905c96cae4ddf" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=XVIVO+Perfusion&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=200&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 200, "pagination": "row-offset", "query_text": "XVIVO Perfusion", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "83b901f8c7b0f18bd55e74707ae84d53513a5d63f6fed0196f701001097e69a2" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=XVIVO+Perfusion&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=300&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 300, "pagination": "row-offset", "query_text": "XVIVO Perfusion", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 32, "new_rows": 32, "total_count": null, "from_cache": false, "body_sha256": "830ece284823d3bdd1d259689757e905e5fc27d0bc6c8e810cefdbbffb8522a2" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=XVIVO+Perfusion&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=332&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 332, "pagination": "row-offset", "query_text": "XVIVO Perfusion", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "a0e4422866403fc484250102ed249f0dfe324ba32ade3ead603a3d71a804a955" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=XVIVO+Perfusion&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "sv", "start": 0, "pagination": "row-offset", "query_text": "XVIVO Perfusion", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 20, "new_rows": 20, "total_count": null, "from_cache": false, "body_sha256": "72592c0b21b3eefd8d3e6188735d630615b73f6a9b388fc5747e747a9a3d1347" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=XVIVO+Perfusion&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=20&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "sv", "start": 20, "pagination": "row-offset", "query_text": "XVIVO Perfusion", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "803ed10fffb20bfbee34f8b769a0dacd60feb1d18deb9696a58342afe8501843" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=XVIVO+Perfusion&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 0, "pagination": "row-offset", "query_text": "XVIVO Perfusion", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "d130a5046e42915b76f421f30db27662ea2e7211c352ad63b00476a36472af5b" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=XVIVO+Perfusion&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=100&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 100, "pagination": "row-offset", "query_text": "XVIVO Perfusion", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "e44085d2a6b25f07011bc3dd47b231622a1ef2884f2363f02a4b33203799a233" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=XVIVO+Perfusion&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=200&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 200, "pagination": "row-offset", "query_text": "XVIVO Perfusion", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "672560fcc60394746f70c058c3ef1e7a6a7738e0933e13a9f70bf0eb9ce1778a" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=XVIVO+Perfusion&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=300&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 300, "pagination": "row-offset", "query_text": "XVIVO Perfusion", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 30, "new_rows": 30, "total_count": null, "from_cache": false, "body_sha256": "20d77c463ca35e9adb2b419967aa9faa634c5ecaee77b0f14c444ea3c4f427c1" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=XVIVO+Perfusion&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=330&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 330, "pagination": "row-offset", "query_text": "XVIVO Perfusion", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "beeba5b72557cbff8921a70f227303eb6f12b41121a97b3e72de56ee02cdc380" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=XVIVO+Perfusion&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "en", "start": 0, "pagination": "row-offset", "query_text": "XVIVO Perfusion", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 6, "new_rows": 6, "total_count": null, "from_cache": false, "body_sha256": "7e837dc09c0e24fe0859f1b1c847c236bada3b2913e7be42bd35d313a6ac4953" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=XVIVO+Perfusion&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=6&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "en", "start": 6, "pagination": "row-offset", "query_text": "XVIVO Perfusion", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "bd9c05e04ff6560502e6bf3875897cb7834465fc4920a52158db62f481ce3d43" } ], "identity": { "slug": "xvivo", "instrument_id": "TX1194230", "resolved_url": "https://www.nasdaq.com/european-market-activity/shares/xvivo?id=TX1194230" }, "transport": "ordinary-http", "browser_used": false, "query_text": "XVIVO Perfusion", "retrieved_at": "2026-08-04T20:08:14Z" }